Compare BioNTech SE - ADR (BNTX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Exxon Mobil Corporation — how do they compare? BioNTech SE - ADR trades at $93.77 (market cap $23.31B), while Exxon Mobil Corporation trades at $159.12 (market cap $657.08B). The key difference: Exxon Mobil Corporation is far larger — about 28.2× BioNTech SE - ADR's market cap, and Exxon Mobil Corporation pays a 2.58% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | XOM | |
|---|---|---|
Market Cap | $23.31B | $657.08B |
Sector | Health | Energy |
52-Week High | $119.34 | $171.52 |
52-Week Low | $83.89 | $106.13 |
Enterprise Value | $6.60B | $688.86B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
ExxonMobil (XOM) trades at $159.79, up 4.48% today, showing strong momentum near its consensus price target of $163.71. The stock maintains a bullish technical outlook with support at $156 and resistance at $162. Recent earnings show mixed results with Q2 2026 missing expectations, but profitability remains solid with a 9.07% net margin and 12.55% ROE. The company benefits from high oil prices and strategic Permian Basin operations, though revenue has declined from $398.7B in 2022 to $323.9B in 2025.
XOM presents a balanced investment case with analyst consensus leaning toward Hold (51.85%). Upside potential exists from oil price strength and operational efficiency, but risks include volatile energy markets and declining revenue trends. The stock's current valuation at 20.57x P/E appears reasonable given stable dividends and strong cash flow generation. Institutional sentiment remains cautiously optimistic with price targets suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
